CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors.

ABSTRACT:

Background

Adaptive cellular therapy (ACT), particularly chimeric antigen receptor (CAR)-T cell therapy, has been successful in the treatment of hemopoietic malignancies. However, poor trafficking of administered effector T cells to the tumor poses a great hurdle for this otherwise powerful therapeutic approach in solid cancers. Our previous study revealed that targeting CD93 normalizes tumor vascular functions to improve immune checkpoint blockade therapy. The objective of this study is to evaluate whether CD93 blockade improves ACT in solid cancers.

Methods

Monoclonal antibodies (mAbs) against CD93 or IGFBP7 were administered in implanted mouse melanoma models to assess the effect of CD93 blockade on ACT. Different sources of effector T cells were used, including pre-activ

SUBMITTER: Sun Y 

PROVIDER: S-EPMC11749055 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature